Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia

Radzikowska, E; Roży, Adriana; Jaguś, Paulina; Polubiec-Kownacka, Małgorzata; Wiatr, Elżbieta; Chorostowska‐Wynimko, Joanna; Roszkowski‐Śliż, Kazimierz

doi:10.17219/acem/61953

Cited by 14 publications

(15 citation statements)

References 22 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As reported by many studies, pro-inflammatory mediators are hyperactivated in both COP and OP and this seems to be the main reason for the efficacy of anti-inflammatory therapies in this disease [41][42][43][44].…”

Section: Macrolides In Organising Pneumoniamentioning

confidence: 74%

“…RADZIKOWSKA et al [44] reported a decrease in serum concentration of pro-inflammatory cytokines, including IL-6, IL-8 and transforming growth factor-β1, and in the BAL concentration of IL-6 in patients with biopsy-proven COP who responded to clarithromycin 500 mg twice daily for 3 months. Moreover, AOKI and KAO [50] showed that the anti-inflammatory effect of erythromycin is also expressed at the level of cytotoxic T-lymphocytes.…”

Section: Macrolides In Organising Pneumoniamentioning

confidence: 99%

See 1 more Smart Citation

Long-term macrolides in diffuse interstitial lung diseases

Faverio¹,

Bini²,

Vaghi³

et al. 2017

Eur Respir Rev

View full text Add to dashboard Cite

In the present review we provide currently available evidence for the use of macrolides in the treatment of diffuse interstitial lung diseases (ILDs). Up to now, research on macrolides has mainly focused on three areas. First, macrolides have shown some promising results in cellular models and case reports as antifibrotic agents, by promoting autophagy and clearance of intracellular protein aggregates and acting as regulators of surfactant homeostasis. Secondly, macrolides have an immunomodulatory effect, which has been applied in some organising pneumonia cases. In particular, macrolides have been tested in association with systemic corticosteroids as steroid-sparing agents and alone as either first-line agents in mild cases or second-line agents where steroids were poorly tolerated or had failed. Thirdly, a recent area of research concerns the possible role of macrolides as modulators of lung microbiota and the host-microbiota interaction. This function has been particularly studied in idiopathic pulmonary fibrosis patients, in whom changes in microbiota have been proved to be associated with disease progression. However, the lack of high-quality studies makes the application of macrolide therapy in ILDs a field in which research should be conducted on a large scale.

show abstract

Section: Macrolides In Organising Pneumoniamentioning

confidence: 74%

Section: Macrolides In Organising Pneumoniamentioning

confidence: 99%

Long-term macrolides in diffuse interstitial lung diseases

Faverio¹,

Bini²,

Vaghi³

et al. 2017

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…Inflammatory cytokines produced by alveolar macrophages including interleukin (IL)-6, IL-8 and transforming growth factor-β1 play an important role in the pathogenesis of organising pneumonia 14. Macrolides inhibit cytokine production by the alveolar macrophages decreasing their concentration in the serum and bronchoalveolar lavage in patients with organising pneumonia 14–16. The anti-inflammatory effects of macrolides are the basis of their effectiveness in the treatment of organising pneumonia14–16 and other diseases including chronic obstructive pulmonary disease, cystic fibrosis and panbronchiolitis.…”

Section: Discussionmentioning

confidence: 99%

“…Macrolides inhibit cytokine production by the alveolar macrophages decreasing their concentration in the serum and bronchoalveolar lavage in patients with organising pneumonia 14–16. The anti-inflammatory effects of macrolides are the basis of their effectiveness in the treatment of organising pneumonia14–16 and other diseases including chronic obstructive pulmonary disease, cystic fibrosis and panbronchiolitis. Macrolides have been successfully used to treat cryptogenic and secondary organising pneumonia either alone or in combination with corticosteroids 17–19.…”

Section: Discussionmentioning

confidence: 99%

Acute fibrinous organising pneumonia presenting as a cavitary lung lesion and treatment response to azithromycin

et al. 2019

View full text Add to dashboard Cite

Acute fibrinous organising pneumonia is distinct from the classic diffuse alveolar damage, organising pneumonia and eosinophilic pneumonia. A 52-year-old woman presented with fever, productive cough, night sweats and left-sided pleuritic chest pain for a week. Physical examination was significant only for decreased breath sounds in the left infraclavicular area laterally. Imaging studies revealed a peripheral thick-walled left upper lobe cavitary lesion, left lower lobe consolidation and an enlarged subcarinal lymph node. She was treated with doxycycline for 10 days without improvement. Pertinent laboratory tests, microbiologic workup and fibre-optic bronchoscopy were non-diagnostic and a CT-guided left upper lobe lung biopsy revealed acute fibrinous organising pneumonia. She was treated with azithromycin with complete resolution of symptoms. To our knowledge, this is the first reported case of acute fibrinous organising pneumonia presenting as a cavitary lung lesion and the first with treatment response to azithromycin.

show abstract

“…The evidence base for macrolide therapy in OP consists of case reports and small case series totalling fewer than 50 patients 151–161. Macrolides were used either first-line in untreated patients or less commonly, as an add-on therapy with oral steroids.…”

Section: Section 8: the Use Of Macrolides For Other Respiratory Condimentioning

confidence: 99%

British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease

Smith

Rand

Addy

et al. 2020

Thorax

View full text Add to dashboard Cite

Clarithromycin Decreases IL-6 Concentration in Serum and BAL Fluid in Patients with Cryptogenic Organizing Pneumonia

Cited by 14 publications

References 22 publications

Long-term macrolides in diffuse interstitial lung diseases

Long-term macrolides in diffuse interstitial lung diseases

Acute fibrinous organising pneumonia presenting as a cavitary lung lesion and treatment response to azithromycin

British Thoracic Society guideline for the use of long-term macrolides in adults with respiratory disease

Contact Info

Product

Resources

About